請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/47316
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 柯逢春 | |
dc.contributor.author | Chia-Chi Chang | en |
dc.contributor.author | 張佳琦 | zh_TW |
dc.date.accessioned | 2021-06-15T05:54:44Z | - |
dc.date.available | 2010-08-19 | |
dc.date.copyright | 2010-08-19 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-08-17 | |
dc.identifier.citation | 1. DeBerardinis, R.J., Lum, J.J., Hatzivassiliou, G. and Thompson1, C.B. (2008). The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation. Cell Metabolism 7, 11-20.
2. Bauer, D.E., Harris, M.H., Plas, D.R., Lum, J.J., Hammerman, P.S., Rathmell, J.C., Riley, J.L. and Thompson, C.B. (2004). Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand. FASEB J. 18, 1303–1305. 3. Bauer, D.E., Hatzivassiliou, G., Zhao, F., Andreadis, C. and Thompson, C.B. (2005). ATP citrate lyase is an important component of cell growth and transformation. Oncogene 24, 6314-6322. 4. Hatzivassiliou, G., Zhao, F., Bauer, D.E., Andreadis, C., Shaw, A.N., Dhanak, D., Hingorani, S.R., Tuveson, D.A. and Thompson, C.B. (2005). ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8, 311-321. 5. Kuhajda, F.P., Jenner, K., Wood, F.D., Hennigar, R.A., Jacobs, L.B., Dick, J.D. and Pasternack, G.R. (1994). Fatty acid synthesis: a potential selective target for antineoplastic therapy. Proc. Natl. Acad. Sci. 91, 6379-6383. 6. Pizer, E.S., Wood, F.D., Heine, H.S., Romantsev, F.E., Pasternack, G.R. and Kuhajda, F.P. (1996). Inhibition of fatty acid synthesis delays disease progression in a xenograft model of ovarian cancer. Cancer Res. 56, 1189-1193. 7. Christofk, H.R. et al. (2008). The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230-233. 8. Warburg, O. (1925). Uber den Stoffwechsel der Carcinomzelle. Klin. Wochenschr. 4, 534-536. 9. Warburg, O. (1956). On the origin of cancer cells. Science 123, 309-314. 10. Fantin, V.R., St-Pierre, J. and Leder, P. (2006). Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9, 425-434. 11. Marjanovic, S., Eriksson, I. and Nelson, B.D. (1990). Expression of a new set of glycolytic isozymes in activated human peripheral lymphocytes. Biochim. Biophys. Acta 1087, 1-6. 12. Shim, H., Dolde, C., Lewis, B.C., Wu, C.S., Dang, G., Jungmann, R.A., Dalla- Favera, R. and Dang, C.V. (1997). c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl. Acad. Sci. 94, 6658-6663. 13. Parlo, R.A. and Coleman, P.S. (1984). Enhanced rate of citrate export from cholesterol-rich hepatoma mitochondria. The truncated Krebs cycle and other metabolic ramifications of mitochondrial membrane cholesterol. J. Biol. Chem. 259, 9997-10003. 14. DeBerardinis, R.J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S. and Thompson, C.B. (2007). Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl. Acad. Sci. 104, 19345-19350. 15. Eagle, H., Oyama, V.I., Levy, M., Horton, C.L. and Fleischman, R. (1956). The growth response of mammalian cells in tissue culture to L-glutamine and L-glutamic acid. J. Biol. Chem. 218, 607-616. 16. Kovacevic, Z. and McGivan, J.D. (1983). Mitochondrial metabolism of glutamine and glutamate and its physiological significance. Physiol. Rev. 63, 547-605. 17. Franke, T.F., Hornik, C.P., Segev, L., Shostak, G.A. and Sugimoto, C. (2003). PI3K/Akt and apoptosis: size matters. Oncogene 22, 8983-8998. 18. Edinger, A.L. and Thompson, C.B. (2002). Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell 13, 2276-2288. 19. Roos, S., Jansson, N., Palmberg, I., Saljo, K., Powell, T.L. and Jansson, T. (2007). Mammalian target of rapamycin in the human placenta regulates leucine transport and is down-regulated in restricted fetal growth. J. Physiol. 582, 449-459. 20. Wieman, H.L., Wofford, J.A. and Rathmell, J.C. (2007). Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol. Biol. Cell 18, 1437-1446. 21. Xu, R.H., Pelicano, H., Zhang, H., Giles, F.J., Keating, M.J. and Huang, P. (2005). Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia 19, 2153-2158. 22. Elstrom, R.L., Bauer, D.E., Buzzai, M., Karnauskas, R., Harris, M.H., Plas, D.R., Zhuang, H., Cinalli, R.M., Alavi, A., Rudin, C.M. and Thompson, C.B. (2004). Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 64, 3892-3899. 23. Rathmell, J.C., Fox, C.J., Plas, D.R., Hammerman, P.S., Cinalli, R.M. and Thompson, C.B. (2003). Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol. Cell. Biol. 23, 7315-7328. 24. Gingras, A.C., Raught, B. and Sonenberg, N. (2001). Regulation of translation initiation by FRAP/mTOR. Genes Dev. 15, 807-826. 25. Hay, N. and Sonenberg, N. (2004). Upstream and downstream of mTOR. Genes & Dev. 18, 1926-1945. 26. Chang, Y., Wang, J., Lu, X., Thewke, D.P. and Mason, R.J. (2005). KGF induces lipogenic genes through a PI3K and JNK/SREBP-1 pathway in H292 cells. J. Lipid Res. 46, 2624-2635. 27. Brand, K. (1985). Glutamine and glucose metabolism during thymocyte proliferation. Pathways of glutamine and glutamate metabolism. Biochem. J. 228, 353-361. 28. DeBerardinis, R.J., Lum, J.J. and Thompson, C.B. (2006). Phosphatidylinositol 3-kinase-dependent modulation of carnitine palmitoyltransferase 1A expression regulates lipid metabolism during hematopoietic cell growth. J. Biol. Chem. 281, 37372-37380. 29. Forbes, N.S., Meadows, A.L., Clark, D.S. and Blanch, H.W. (2006). Estradiol stimulates the biosynthetic pathways of breast cancer cells: detection by metabolic flux analysis. Metab. Eng. 8, 639-652. 30. Adhikary, S. and Eilers, M. (2005). Transcriptional regulation and transformation by Myc proteins. Nature Rev. Mol. Cell Biol. 6, 635-645. 31. Mamane, Y., Petroulakis, E., Rong, L., Yoshida, K., Ler, L.W. and Sonenberg, N. (2004). eIF4E--from translation to transformation. Oncogene 23, 3172-3179. 32. Ruggero,D., Montanaro, L., Ma, L., Xu, W., Londei, P., Cordon-Cardo, C. and Pandolfi, P.P. (2004). The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nature Medicine 10, 484-486. 33. Dang, C.V. et al. (2006). The c-Myc target gene network. Semin. Cancer Biol. 16, 253-264. 34. Osthus, R.C., Shim, H., Kim, S., Li, Q., Reddy, R., Mukherjee, M., Xu, Y., Wonsey, D., Lee, L.A. and Dang, C.V. (2000). Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J. Biol. Chem. 275, 21797-21800. 35. Gomez-Roman, N., Grandori, C., Eisenman, R.N. and White, R.J. (2003). Direct activation of RNA polymerase III transcription by c-Myc. Nature 421, 290-294. 36. Grandori, C. et al. (2005). c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I. Nature Cell Biol. 7, 311–318. 37. Grewal, S.S., Li, L., Orian, A., Eisenman, R.N. and Edgar, B.A. (2005). Myc-dependent regulation of ribosomal RNA synthesis during Drosophila development. Nature Cell Biol. 7, 295-302. 38. Schreiber-Agus, N. et al. (1997). Drosophila Myc is oncogenic in mammalian cells and plays a role in the diminutive phenotype. Proc. Natl Acad. Sci. 94, 1235-1240. 39. Gallant, P., Shiio, Y., Cheng, P.F., Parkhurst, S.M. and Eisenman, R.N. (1996). Myc and Max homologs in Drosophila. Science 274, 1523-1527. 40. Arabi, A., Wu, S., Ridderstrale, K., Bierhoff, H., Shiue, C., Fatyol, K., Fahlen, S., Hydbring, P., Soderberg, O., Grummt, I., et al. (2005). c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription. Nat. Cell Biol. 7, 303-310. 41. Coller, H.A., Grandori, C., Tamayo, P., Colbert, T., Lander, E.S., Eisenman, R.N. and Golub, T.R. (2000). Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc. Natl. Acad. Sci. 97, 3260-3265. 42. O'Connell, B.C., Cheung, A.F., Simkevich, C.P., Tam, W., Ren, X., Mateyak, M.K. and Sedivy, J.M. (2003). A large scale genetic analysis of c-Myc-regulated gene expression patterns. J. Biol. Chem. 278, 12563-12573. 43. Guo, Q.M., Malek, R.L., Kim, S., Chiao, C., He, M., Ruffy, M., Sanka, K., Lee, N.H., Dang, C.V. and Liu, E.T. (2000). Identification of c-myc responsive genes using rat cDNA microarray. Cancer Res. 60, 5922-5928. 44. Nikiforov, M.A., Chandriani, S., O’Connell, B., Petrenko, O., Kotenko, I., Beavis, A., Sedivy, J.M. and Cole, M.D. (2002). A functional screen for Mycresponsive genes reveals serine hydroxymethyltransferase, a major source of the one-carbon unit for cell metabolism. Mol. Cell. Biol. 22, 5793-5800. 45. Christofk, H.R., Vander Heiden, M.G., Wu, N., Asara, J.M. and Cantley, L.C. (2008). Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452, 181-186. 46. Li, F., Wang, Y., Zeller, K.I., Potter, J.J., Wonsey, D.R., O’Donnell, K.A., Kim, J.W., Yustein, J.T., Lee, L.A. and Dang, C.V. (2005). Myc Stimulates Nuclearly Encoded Mitochondrial Genes and Mitochondrial Biogenesis. Mol. Cell. Biol. 25, 6225-6234. 47. Fernandez, P.C., Frank, S.R., Wang, L., Schroeder, M., Liu, S., Greene, J., Cocito, A. and Amati, B. (2003). Genomic targets of the human c-Myc protein. Genes Dev. 17, 1115-1129. 48. Menssen, A. and Hermeking, H. (2002). Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl. Acad. Sci. 99, 6274-6279. 49. Morrish, F., Giedt, C. and Hockenbery, D. (2003). c-MYC apoptotic function is mediated by NRF-1 target genes. Genes Dev. 17, 240-255. 50. Orian, A., van Steensel, B., Delrow, J., Bussemaker, H.J., Li, L., Sawado, T., Williams, E., Loo, L.W., Cowley, S.M., Yost, C., Pierce, S., Edgar, B.A., Parkhurst, S.M. and Eisenman, R.N. (2003). Genomic binding by the Drosophila Myc, Max, Mad/Mnt transcription factor network. Genes Dev. 17, 1101-1114. 51. Watson, J.D., Oster, S.K., Shago, M., Khosravi, F., and Penn, L.Z. (2002). Identifying genes regulated in a Myc-dependent manner. J. Biol. Chem. 277, 36921-36930. 52. Wonsey, D.R., Zeller, K.I. and Dang, C.V. (2002). The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proc. Natl. Acad. Sci. 99, 6649-6654. 53. Zhang, H., Gao, P., Fukuda, R., Kumar, G., Krishnamachary, B., Zeller, K.I., Dang, C.V. and Semenza, G.L. (2007). HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11, 407-420. 54. Wise, D.R., DeBerardinis, R.J., Mancuso, A., Sayed, N., Zhang, Xiao-Y., Pfeiffer, H.K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S.B. and Thompson, C.B. (2008) Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci.105, 18782-18787. 55. P6. Gao, P., Tchernyshyov, I., Chang, T.C., Lee, Y.S., Kita, K., Ochi, T., Zeller, K.I., De Marzo, A.M., Van Eyk, J.E., Mendell, J.T. and Dang, C.V. (2009). c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458, 762-765. 56. Wang, G.L., Jiang, B.H., Rue, E.A. and Semenza, G.L. (1995). Hypoxia-inducible factor 1 is a basic-helixloop- helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. 92, 5510-5514. 57. Kaelin, W.G. (2005). Proline hydroxylation and gene expression. Annu Rev Biochem. 74, 115-128. 58. Cramer, T., Yamanishi, Y., Clausen, B.E., Forster, I., Pawlinski, R., Mackman, N., Haase, V.H., Jaenisch, R., Corr, M., Nizet, V., et al. (2003). HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 112, 645-657. 59. Jiang, B.H., Jiang, G., Zheng, J.Z., Lu, Z., Hunter, T. and Vogt, P.K. (2001). Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 12, 363-369. 60. Majumder, P.K., Febbo, P.G., Bikoff, R., Berger, R., Xue, Q., McMahon, L.M., Manola, J., Brugarolas, J., McDonnell, T.J., Golub, T.R., et al. (2004). mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med. 10, 594-601. 61. Bruick, R.K. and McKnight, S.L. (2001). A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294, 1337-1340. 62. Epstein, A.C., Gleadle, J.M., McNeill, L.A., Hewitson, K.S., O’Rourke, J., Mole, D.R. et al. (2001). C.elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43-54. 63. Maxwell, P.H., Wiesener, M.S., Chang, G.W., Clifford, S.C., Vaux, E.C., Cockman, M.E. et al. (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275. 64. Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M. et al. (2001). HIFalpha targeted for VHLmediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464-468. 65. Jaakkola, P., Mole, D.R., Tian, Y.M., Wilson, M.I., Gielbert, J., Gaskell, S.J. et al. (2001). Targeting of HIFalpha to the von Hippel–Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468-472. 66. Schofield, C.J. and Ratcliffe, P.J. (2005). Signalling hypoxia by HIF hydroxylases. Biochem Biophys Res Commun 338, 617-626. 67. Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B. and Gottlieb, E. (2005). Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 7, 77-85. 68. Baysal, B.E., Ferrell, R.E., Willett-Brozick, J.E., Lawrence, E.C., Myssiorek, D., Bosch, A., van der Mey, A., Taschner, P.E., Rubinstein, W.S., Myers, E.N., Richard, C.W., Cornelisse, C.J., Devilee, P. and Devlin, B. (2000). Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287, 848-51. 69. Pollard, P.J., Wortham, N.C. and Tomlinson, I.P. (2003). The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase. Ann. Med. 35, 632-639. 70. Hagen, T., Taylor, C.T., Lam, F. and Moncada, S. (2003). Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha. Science 302, 1975-1978. 71. Wiesener, M.S., Jurgensen, J.S., Rosenberger, C., Scholze, C.K., Horstrup, J.H., Warnecke, C., Mandriota, S., Bechmann, I., Frei, U.A., Pugh, C.W., et al. (2003). Widespread hypoxia-inducible expression of HIF-2 in distinct cell populations of different organs. FASEB J. 17, 271-273. 72. Hervouet, E., Demont, J., Pecina, P., Vojtiskova, A., Houstek, J., Simonnet, H. and Godinot, C. (2005). A new role for the von Hippel-Lindau tumor suppressor protein: stimulation of mitochondrial oxidative phosphorylation complex biogenesis. Carcinogenesis 26, 531-539. 73. Covello, K.L., Kehler, J., Yu, H., Gordan, J.D., Arsham, A.M., Hu, C.J., Labosky, P.A., Simon, M.C. and Keith, B. (2006). HIF-2α regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 20, 557-570. 74. Koshiji, M., To, K.K., Hammer, S., Kumamoto, K., Harris, A.L., Modrich, P. and Huang, L.E. (2005). HIF-1 induces genetic instability by transcriptionally downregulating MutS expression. Mol. Cell 17, 793-803. 75. To, K.K., Sedelnikova, O.A., Samons, M., Bonner, W.M. and Huang, L.E. (2006). The phosphorylation status of PAS-B distinguishes HIF-1α from HIF-2α in NBS1 repression. EMBO J. 25, 4784-4794. 76. Koshiji, M., Kageyama, Y., Pete, E.A., Horikawa, I., Barrett, J.C. and Huang, L.E. (2004). HIF-1α induces cell cycle arrest by functionally counteracting Myc. EMBO J. 23, 1949-1956. 77. Gordan, J.D., Bertout, J.A., Hu, C.J., Diehl, J.A. and Simon, M.C. (2007). HIF-2α Promotes Hypoxic Cell Proliferation by Enhancing c-Myc Transcriptional Activity. Cancer Cell 11, 335-347. 78. Mazure, N.M., Chauvet, C., Bois-Joyeux, B., Bernard, M.A., Nacer- Cherif, H., and Danan, J.L. (2002). Repression of {alpha}-Fetoprotein Gene Expression under Hypoxic Conditions in Human Hepatoma Cells: Characterization of a Negative Hypoxia Response Element That Mediates Opposite Effects of Hypoxia Inducible Factor-1 and c-Myc. Cancer Res. 62, 1158-1165. 79. Kim, J.W., Tchernyshyov, I., Semenza, G.L. and Dang, C.V. (2006). HIF-1- mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 3, 177-185. 80. Papandreou, I., Cairns, R.A., Fontana, L., Lim, A.L. and Denko, N.C. (2006). HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 3, 187-197. 81. Lum, J.J., Bui, T., Gruber, M., Gordan, J.D., Deberardinis, R.J., Covello, K.L., Simon, M.C. and Thompson, C.B. (2007). The transcription factor HIF-1{alpha} plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis. Genes Dev. 21, 1037-1049. 82. Brugarolas, J. and Kaelin, W.G. (2004). Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell 6, 7-10. 83. Reiling, J.H., and Hafen, E. (2004). The hypoxia-induced paralogs Scylla and Charybdis inhibit growth by down-regulating S6K activity upstream of TSC in Drosophila. Genes Dev. 18, 2879-2892. 84. Sofer, A., Lei, K., Johannessen C.M., and Ellisen, L. W. (2005). Regulation of mTOR and Cell Growth in Response to Energy Stress by REDD1. Molecular and Cellular Biology 25, 5834-5845. 85. Schwarzer, R., Tondera, D., Arnold, W., Giese, K., Klippel, A. and Kaufmann, J. (2005). REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase. Oncogene 24, 1138-1149. 86. Malumbres, M. and Barbacid, M. (2001). To cycle or not to cycle: a critical decision in cancer. Nature Rev. Cancer 1, 222-231. 87. Kops, G.J., Weaver, B.A. and Cleveland, D.W. (2005). On the road to cancer: aneuploidy and the mitotic checkpoint. Nature Rev. Cancer 5, 773-785. 88. Ortega, S., Malumbres, M. and Barbacid, M. (2002). Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim. Biophys. Acta 1602, 73-87. 89. Matsushime, H., Roussel, M.F., Ashmun, R.A. and Sherr, C.J. (1991). Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 65, 701-713. 90. Matsushime, H., Quelle, D.E., Shurtleff, S.A., Shibuya, M., Sherr, C.J. and Kato, J.Y. (1994). D-type cyclin-dependent kinase activity in mammalian cells. Mol. Cell Biol. 14, 2066-2076. 91. Sherr, C.J. (1996). Cancer cell cycles. Science 274, 1672-1677. 92. Sherr, C.J. and Roberts, J.M. (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501-1512. 93. Cobrinik, D. (2005). Pocket proteins and cell cycle control. Oncogene 24, 2796-2809 94. Beijersbergen, R.L. and Bernards, R. (1996). Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins. Biochim Biophys Acta. 1287, 103-120. 95. Harbour, J.W., Luo, R.X., Dei Santi, A., Postigo, A.A. and Dean, D.C. (1999). Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98, 859-869. 96. Lundberg, A.S. and Weinberg, R.A. (1998). Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclincdk complexes. Mol. Cell. Biol. 18, 753-761. 97. Dyson, N. (1998). The regulation of E2F by pRB-family proteins. Genes Dev. 12, 2245-2262. 98. Malumbres, M. and Barbacid, M. (2009). Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 9, 153-66. 99. Sotillo, R. et al. (2001). Wide spectrum of tumors in knock in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J. 20, 6637-6647. 100. Kozar, K., Ciemerych, M.A., Rebel, V.I., Shigematsu, H., Zagozdzon, A., Sicinska, E., Geng, Y., Yu, Q., Bhattacharya, S., Bronson, R.T., et al. (2004). Mouse development and cell proliferation in the absence of d-cyclins. Cell 118, 477-491. 101. Malumbres, M., Sotillo, R., Santamaria, D., Galan, J., Cerezo, A., Ortega, S., Dubus, P. and Barbacid, M. (2004). Mammalian Cells Cycle without the D-Type Cyclin-Dependent Kinases Cdk4 and Cdk6. Cell 118, 493-504. 102. Tsutsui, T., Hesabi, B., Moons, D.S., Pandolfi, P.P., Hansel, K.S., Koff, A. and Kiyokawa, H. (1999). Targeted disruption of CDK4 delays cell cycle entry with enhanced p27 (Kip1) activity. Mol. Cell Biol. 19, 7011-7019. 103. Jiang, W., Kahn, S.M., Zhou, P., Zhang, Y.J., Cacace, A.M., Infante, A.S., Doi, S., Santella, R.M. and Weinstein, I.B. (1993). Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene 8, 3447-3457. 104. Quelle, D.E., Ashmun, R.A., Shurtleff, S.A., Kato, J-y., Bar-Sagi, D., Rousel, M.F. and Sherr, C.J. (1993). Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev. 7, 1559-1571. 105. Resnitzky, D., Gossen, M., Bujard, H. and Reed, S.I. (1994). Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol. Cell Biol. 14, 1669-1679. 106. Herrera, R.E., Sah, V.P., Williams, B.O., Mäkelä, T.P., Weinberg, R.A. and Jacks, T. (1996). Altered cell cycle kinetics, gene expression and G1 restriction point regulation in Rb-deficient fibroblasts. Mol Cell Biol 16, 2402-2407. 107. Frei, C. and Edgar, B.A. (2004). Drosophila Cyclin D/Cdk4 requires Hif-1 prolyl hydroxylase to drive cell growth. Developmental Cell 6, 241–251. 108. Datar, S.A., Jacobs, H.W., de la Cruz, A.F., Lehner, C.F. and Edgar, B.A. (2000). The Drosophila cyclin D-Cdk4 complex promotes cellular growth. EMBO J. 19, 4543-4554. 109. Meyer, C.A., Jacobs, H.W., Datar, S.A., Du, W., Edgar, B.A. and Lehner, C.F. (2000). Drosophila Cdk4 is required for normal growth and is dispensable for cell cycle progression. EMBO J 19, 4533-4542. 110. Emmerich, J., Meyer, C.A., de la Cruz, A.F., Edgar, B.A. and Lehner, C.F. (2004). Cyclin D does not provide essential cdk4-independent functions in Drosophila. Genetics 168, 867-875. 111. Soni, R., Muller, L., Furet, P., Schoepfer, J., Stephan, C., Zumstein-Mecker, S., Fretz, H. and Chaudhuri, B. (2000). Inhibition of Cyclin-Dependent Kinase 4 (Cdk4) by Fascaplysin, a Marine Natural Product. Biochemical and Biophysical Research Communications 275, 877-884. 112. Roll, D.M., Ireland, C.M., Lu, H.S.M. et al. (1988). Fascaplysin, an unusual antimicrobial pigment from the marine sponge Fascaplysinopsis sp . J Org Chem. 53, 3276-3278. 113. Segraves, N.L., Lopez, S., Johnson, T.A. et al. (2003). Structures and cytotoxicities of fascaplysin and related alkaloids from two marine phyla—Fascaplysinopsis sponges and Didemnum tunicates. Tetrahedron Lett. 44, 3471-3475. 114. Hinnebusch, A.G. (2000). in Translational Control of Gene Expression (Sonenberg, N., Hershey, J.W.B. and Mathews, M., eds.), pp. 185-244, Cold Spring Harbor Laboratory Press, Cold Spring Harbor , NY. 115. Wek, R.C., Staschke, K.A. and Narasimhan, J. (2004). in Nutrient-induced responses in eukaryotic cells, vol. 7 (Winderickx, J. and Taylor, P.M., eds.), pp. 171-199, Springer-Verlag, Berlin 116. Wek, R.C., Jiang, H.-Y. and Anthony, T.G. (2006). Coping with stress: eIF2 kinases and translational control. Biochemical Society Transactions 34, 7-11. 117. K13. Kaufman, R.J. (2004). Regulation of mRNA translation by protein folding in the endoplasmic reticulum. Trends Biochem. Sci. 29, 152-158. 118. Fant, V., Stamp, G., Andrews, A., Rosewel, I. and Dickson, C. (1995). Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev. 9, 2364-2372. 119. Sicinski, P. et al. (1996). Cyclin D2 is a FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 384, 470-474. 120. Rane, S.G., Dubus, P., Mettus, R.V., Galbreath, E.J., Boden, G., Reddy, E.P. and Barbacid, M. (1999). Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia. Nature Genet. 22, 44-52. 121. Yu, Q. et al. (2001). Specific protection against breast cancers by cyclin D1 ablation. Nature 411, 1017-1021. 122. Zou, X. et al. (2002). Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev. 16, 2923-2934. 123. Miliani de Marval, P.L. et al. (2004). Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues. Mol. Cell. Biol. 24, 7538-7547. 124. Lamb, J., Ramaswamy, S., Ford, H.L., Contreras, B., Martinez, R.V., Kittrell, F.S., Zahnow, C.A., Patterson, N., Golub, T.R. and Ewen, M.E. (2003). A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 114, 323-34. 125. Neufeld, T.P., de la Cruz, A.F.A., Johnston, L.A. and Edgar, B.A. (1998) Coordination of growth and cell division in the Drosophila wing. Cell 93, 1183-1193. 126. Lu, X.L., Zheng, Y.L., Chen, H.M., Yan, X.J., Wang, F. and Xu, W.F. (2009). Anti-proliferation of human cervical cancer HeLa cell line by fascaplysin through apoptosis induction. Yao Xue Xue Bao. 44, 980-986. 127. Sarbassov, D., Ali, S.M. and Sabatini, D.M. (2005). Growing roles for the mTOR pathway. Curr. Opin. Cell Biol. 17, 596-603. 128. Wullschleger, S., Loewith, R. and Hall, M.N. (2006). TOR signaling in growth and metabolism. Cell 124, 471-484. 129. Manning, B.D. (2004). Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J. Cell Biol. 167, 399-403. 130. Zick, Y. (2005). Ser/Thr phosphorylation of IRS proteins: A molecular basis for insulin resistance. Sci STKE. 25, 268. P4. 131. Zhang, H., Bajraszewski, N., Wu, E., Wang, H., Moseman, A.P., Dabora, S.L., Griffin, J.D. and Kwiatkowski, D.J. (2007). PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin. Invest. 117, 730-738. 132. Xin, S., Weng, L., Xu, J. and Du, W. (2002). The role of RBF in developmentally regulated cell proliferation in the eye disc and in Cyclin D/ Cdk4 induced cellular growth. Development 129, 1345-1356. 133. Frei, C. (2004). Cyclin D/Cdk4: new insights from Drosophila. Cell Cycle 3, 558-560. 134. Frazier, M.R., Woods, H.A., and Harrison, J.F. (2001). Interactive effects of rearing temperature and oxygen on the development of Drosophila melanogaster. Physiol Biochem Zool 74, 641-650. 135. Frei, C., Galloni, M., Hafen, E. and Edgar, B.A. (2005). The Drosophila mitochondrial ribosomal protein mRpL12 is required for Cyclin D/Cdk4-driven growth. The EMBO Journal 24, 623–634. 136. Datar, S.A., Galloni, M., de la Cruz, A., Marti, M., Edgar, B.A., Frei, C. (2006) Mammalian cyclin D1/Cdk4 complexes induce cell growth in Drosophila. Cell Cycle 6, 647-52. 137. Hirsila, M., Koivunen, P., Gunzler, V., Kivirikko, K.I. and Myllyharju, J. (2003). Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J. Biol. Chem. 278, 30772-30780. 138. Huang, J., Zhao, Q., Mooney, S.M., Lee, F.S. (2002). Sequence determinants in hypoxia-inducible factor-1α for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3. J. Biol. Chem. 277, 39792-39800. 139. Lieb, M.E., Menzies, K., Moschella, M.C., Ni, R. and Taubman, M.B. (2002). Mammalian EGLN genes have distinct patterns of mRNA expression and regulation. Biochem. Cell Biol. 80, 421-426. 140. Rohrbach, S., Simm, A., Pregla, R., Franke, C. and Katschinski, D.M. (2005). Age-dependent increase of prolyl-4-hydroxylase domain (PHD) 3 expression in human and mouse heart. Biogerontology 6, 165-171. 141. Menzies, K., Liu, B., Kim, W.J., Moschella, M.C. and Taubman, M.B. (2004). Regulation of the SM-20 prolyl hydroxylase gene in smooth muscle cells. Biochem Biophys Res Commun. 317, 801-810. 142. Köditz, J., Nesper, J., Wottawa, M., Stiehl, D.P., Camenisch, G., Franke, C., Myllyharju, J., Wenger, R.H. and Katschinski, D.M. (2007). Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen sensor. Blood 110, 3610-3617. 143. Rohrbach, S., Teichert, S., Niemann, B., Franke, C. and Katschinski, D.M. (2008). Caloric restriction counteracts age-dependent changes in prolyl-4-hydroxylase domain (PHD) 3 expression. Biogerontology 9, 169-176. 144. Berra, E., Benizri, E., Ginouvès, A., Volmat, V., Roux, D. and Pouysségur, J. (2003). HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J. 22, 4082-4090. 145. Lin, J., Yan, X.J. and Chen, H.M. (2007). Fascaplysin, a selective CDK4 inhibitor, exhibit anti-angiogenic activity in vitro and in vivo. Cancer Chemother Pharmacol 59, 439-445. 146. Zhang, H., Gao, P., Fukuda, R., Kumar, G., Krishnamachary, B., Zeller, K.I., Dang, C.V. and Semenza, G.L. (2007). HIF-1 Inhibits Mitochondrial Biogenesis and Cellular Respiration in VHL-Deficient Renal Cell Carcinoma by Repression of C-MYC Activity. Cancer Cell 11, 407-420. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/47316 | - |
dc.description.abstract | 細胞增生(proliferation)需要由細胞生長(cell growth)的推動,細胞生長進行一連串的巨分子合成增加細胞質量。為了能夠進行細胞生長,細胞代謝狀況需要進行代謝重整(metabolic reprogramming),以利細胞質量(biomass)的累積。Growth factor signaling以及營養訊息匯入PI3K/AKT/mTOR pathway,透過對4E-BP的調控使得c-Myc大量表現,c-Myc與PI3K/AKT/mTOR pathway共同作用促使粒線體(mitochondria)代謝重整以及Warburg effect,造成細胞生長時特殊的代謝狀況,c-Myc也透過下游分子的作用促使粒線體的生成,幫助細胞生長。Hif-1α透過許多層次上的調控抑制c-Myc的活性,影響代謝重整以及粒線體生成,干擾細胞生長,但是Hif-1α同在mTOR/4E-BP pathway調控之下大量表現,Hif-1α必需透過PHD系統不斷分解,PHD系統的活性反應粒線體狀況,正常的粒線體狀況維持PHD系統活性造成Hif-1α大量分解,維持細胞生長的進行。Cdk4/cyclinD1 complex也是促進細胞生長重要的分子,其cyclinD1的表現也在mTOR/4E-BP pathway調控之下,過去Cdk4/cyclinD1 complex的研究集中在G1-S transition的角色,透過對於Rb的作用,促進細胞週期(cell cycle)的進展。但是有些實驗的結果顯示Cdk4/cyclinD1 complex的oncogene功能不是透過對Rb的抑制作用,而是對於細胞生長上有促進的功能。在果蠅系統中Cdk4/cyclinD complex透過Hph(果蠅PHD)執行其細胞生長功能,顯示Cdk4/cyclinD1 complex的活性也影響PHD系統,透露Cdk4/cyclinD1 complex的活性可能參與在c-Myc與Hif-1α之間的分子網絡。
在人類纖維母細胞WI38中,處理Cdk4/cyclin D1 complex活性抑制劑Fascaplysin,抑制Cdk4/cyclin D1 complex的kinase活性,造成細胞週期停止。在Fascaplysin的處理下觀察到Hypoxia-induction factor-1α(Hif-1α)蛋白質累積的現象,但不影響c-Myc的蛋白質總量,進一步的分析發現Fascaplysin藥劑處理下對於Hif-1α蛋白質在Pro564位置的hydroxylation程度沒有顯著影響,而Hif-1α蛋白質生成總量上升,顯示Hif-1α的累積可能是因為蛋白質生成總量上升,而不是透過其分解的途徑受到抑制,此結果顯示Cdk4/cyclin D1 complex的活性參與在Hif-1α蛋白質的調控中,正常的Cdk4/cyclin D complex活性抑制Hif-1α累積,使得Hif-1α不會干擾c-Myc的作用,影響細胞生長的進行。研究中發現Fascaplysin除了影響Hif-1α蛋白質生成總量外,也造成S6K與β-Tublin蛋白質總量受到影響,推測Cdk4/cyclin D1 complex活性可能參與調控mRNA到蛋白質生成的層次,影響蛋白質生成的選擇性。另一方面Fascaplysin處理造成eIF-2α的磷酸化上升,可能造成translation initiation的效率降低,影響蛋白質合成速率。 本實驗透過探討Cdk4/cyclin D1 complex活性抑制劑Fascaplysin對於細胞生長訊息網絡的影響,顯示Cdk4/cyclin D1 complex活性除了過去所知G1-S transition的角色之外,其活性可能也參與在細胞生長的代謝重整、粒線體生成以及蛋白質合成的調控機制中,擁有促進細胞生長的功能。 | zh_TW |
dc.description.abstract | Cell proliferation is driven by cell growth. During cell growth, cells upregulate macromolecular synthesis and thereby increase in size and mass. In order to rapidly accumulate biomass, cells must engage in the metabolic reprogramming. Growth factors and nutrients activate various signal transduction pathways ,and finally upregulate PI3K/AKT/mTOR pathway signaling. During cell growth, mTORC1-4EBP pathway up-regulates c-Myc protein translation. C-Myc assists PI3K/AKT/mTOR pathway in promoting mitochondria metabolic reprogramming and Warburg effect. C-Myc also promotes mitochondria biogenesis through it effects on downstream targets. Hif-1α inhibits c-Myc function by various mechanisms. By the effect on metabolic reprogramming and mitochondria biogenesis, Hif-1α decreases cell growth activity. But Hif-1α expression also under mTORC1-4EBP pathway control, so Hif-1α must be degradated by PHD system during cell growth. PHD system can respond mitochondria’s status, and normal mitochondria activity can maintain PHD activity. During cell growth Hif-1α is continuously expressed and then degradated through PHD regulation. Cdk4/cyclinD1 complex is also the important molecular during cell growth, and cyclin D1 expression also under mTORC1-4EBP pathway control. In the past, the function of Cdk4/cyclinD1 complex mainly focuses on the role of G1-S transition. Cdk4/cyclinD1 complex promotes cell cycle progression via the well characterized Rb/E2F pathway. But some studies show that Cdk4-cyclinD1 complex induces cell transformation by promoting cell growth rather than Rb/E2F pathway. In Drosophila melanogaster, the function of Cdk4-cyclinD complex in promoting cell growth needs Hph(Drosophila PHD). This result shows that Cdk4/cyclinD1 complex might involves in c-Myc and Hif-1α interrelationship.
In human embryonic fibroblast WI38 cells, the Cdk4/cyclin D1 complex activity inhibitor, Fascaplysin induced cell cycle arrest. Fascaplysin induced Hif-1α accumulation, and not interfered c-Myc protein level. Hif-1α accumulation not by decreased the hydroxylation at Pro-564 of Hif-1α, but might through enhanced Hif-1α protein production. These observations show that Cdk4/cyclin D1 complex activity may involves in regulation of Hif-1α protein level. Normal Cdk4/cyclin D1 complex activity assists growth functions of c-Myc by preventing Hif-1α accumulation. We also found that Fascaplysin interfered with the protein levels of S6K and β-Tublin. These results suggest a mechanistic link between Cdk4/cyclin D1 complex activity and regulation of protein levels which involve in cell growth. Fascaplysin treatment increases eIF-2α phosphorylation. This result may decreases protein translation initiation activity, in addition of protein synthesis. In this study, we explore the role of Cdk4/cyclin D1 complex activity during cell growth by using Cdk4/cyclin D1 complex activity inhibitor, Fascaplysin. These results show that Cdk4/cyclin D1 complex activity may have effects in metabolic reprogramming and mitocindria biogenesis through regulation of Hif-1α, and also involve in protein synthesis. Through these functions, Cdk4/cyclin D1 complex can promote cell growth progression. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T05:54:44Z (GMT). No. of bitstreams: 1 ntu-99-R96b43018-1.pdf: 999643 bytes, checksum: 46a6dcb49f9136bcbf0ca070cea1696f (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | 封面……………………………………………………………………….…………. i
誌謝………………………………………………...…………………….…………. ii 中文摘要…………………………………………………………..…….…………. iii 英文摘要……………………………………………………………………..………. v 目錄………………………………………………………….………..….………… viii 圖目錄……………………………………………………………...……...…………. x 引言…………………………………………………………………………………. 1 代謝重組(metabolism reprogram)為細胞生長所需…………………....……… 1 mTOR pathway做為細胞生長的中心調節途徑……………………...……… 3 c-Myc在細胞生長扮演重要的角色…………………………………………… 5 Hif-1與c-Myc的交互作用影響細胞生長方向……………………………… 6 Cdk4-Cyclin D complex的活性促進細胞生長………………………...……… 9 在果蠅系統Cdk4-cyclin D complex活性影響Hph系統……………..……… 11 實驗目的…………………………………………………...……………………….. 13 材料方法……………………………………………………..……….…………….. 15 材料…………………………………………………………………….……… 15 細胞培養………………………………………………………...…………… 15 生長曲線……………………………………………………….……………… 16 細胞內涵物萃取………………………………………………...…………… 16 蛋白質電泳與西方轉漬法…………………………………………….……… 17 結果……………………………………………………...………………………….. 19 抑制Cdk4-Cyclin D complex活性造成細胞週期停滯………………….…… 19 Fascaplysin造成Hif-1α蛋白質的累積……………………………………… 19 抑制Cdk4-cyclin D活性造成Hif-1α蛋白質總量增加………………….…… 20 Fascaplysin不影響Hif-1αPro564的hydroxylation…………………….…… 21 Fascaplysin不影響c-Myc的蛋白質總量…………………………..………… 22 Fascaplysin處理造成S6K與β-Tublin蛋白質總量快速減少…………...…… 22 Fascaplysin處理影響eIF-2α磷酸化的狀況………………………………… 23 討論…………………………………………………………...…………………….. 24 結果圖………………………………………………………..……………………….. 32 參考文獻……………………………………………………………………….…… 41 | |
dc.language.iso | zh-TW | |
dc.title | Cdk4-Cyclin D1對於細胞生長之角色探討 | zh_TW |
dc.title | The role of Cdk4-Cyclin D1 complex in cell growth | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 黃火鍊,李明亭,黃娟娟,蕭培文 | |
dc.subject.keyword | Cdk4/cyclin D1 complex,細胞生長,Fascaplysin,Hif-1α,c-Myc,代謝重整, | zh_TW |
dc.subject.keyword | Cdk4/cyclin D1 complex,Cell growth,Fascaplysin,Hif-1α,c-Myc,Metabolic reprogramming, | en |
dc.relation.page | 63 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2010-08-18 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 分子與細胞生物學研究所 | zh_TW |
顯示於系所單位: | 分子與細胞生物學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf 目前未授權公開取用 | 976.21 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。